NSCLC: tepotinib, first therapy approved against the METex14 skipping alterations.

Diatech Pharmacogenetics at the forefront of the selection of patients!

In Europe, lung cancer is the second most common tumor and the leading cause of cancer-related mortality, responsible for almost 400,000 deaths in 2018.

Genetic alterations of the MET signalling pathway, including mutations leading to MET gene exon 14 (METex14) skipping, are found in 3% to 4% of non-small cell lung cancer (NSCLC) cases and are associated with advanced disease and poor prognosis.

Tepotinib is the first drug approved by the European Commission for the treatment of adult patients with advanced NSCLC harbouring METex14 skipping alterations, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. In about half of patients treated with the MET inhibitor consistent and durable responses to therapy have been reported.

Myriapod^® NGS Cancer panel RNA and EasyPGX^® ready ALK, ROS1, RET, MET are Diatech Pharmacogenetics solutions for oncological molecular analysis that ensure maximum sensitivity and standardization for the detection of the METex14 skipping alterations and the selection of NSCLC patients candidates for therapy with tepotinib.